Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Fineline Cube Mar 30, 2026
Company Deals

Novartis to Acquire Excellergy for Up to $2 Billion, Adding Next-Gen Anti-IgE Antibody Exl-111 to Immunology Pipeline

Fineline Cube Mar 30, 2026
Company Deals

Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond

Fineline Cube Mar 30, 2026
Company Deals

Sinovac Biotech and Indonesia’s Bio Farma Forge Strategic Alliance to Expand Vaccine Access Across Developing Markets

Fineline Cube Mar 30, 2026
Company Deals

BrainAurora Medical Partners with Tokyo Lifestyle to Launch AI-Powered Digital Health Platform for Elderly Cognitive Care Across Asia

Fineline Cube Mar 30, 2026
Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Fineline Cube Mar 26, 2026
Company Drug

Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines

Fineline Cube Mar 30, 2026
Company Drug

AstraZeneca’s Tezspire Gains Dual NMPA Approvals in China for Severe Asthma and Nasal Polyps Based on Pivotal Phase III Data

Fineline Cube Mar 30, 2026
Company Deals

Fosun Pharma to Invest RMB 1B in Chengdu Vaccine Base

Fineline Cube Aug 30, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) announced that its subsidiaries, Shanghai Fosun Pharmaceutical...

Company Drug

InnoCare Pharma and CStone Pharmaceuticals’ Drugs Receive Prioritized CDE Review

Fineline Cube Aug 30, 2022

The Center for Drug Evaluation (CDE) has granted prioritized review status to InnoCare Pharma’s (HKG:...

Company Deals Digital

Luca Healthcare Raises Pre-Series A Funding for Digital Biomarker R&D

Fineline Cube Aug 30, 2022

Shanghai-based Luca Healthcare Co., Ltd, a firm specializing in digital biomarkers and therapeutics, has raised...

Company Drug

Biocytogen and Tracon Pharmaceuticals Gain FDA IND Approval for Sarcoma Trial

Fineline Cube Aug 30, 2022

China-based Biocytogen (Beijing) Co., Ltd and US-based Tracon Pharmaceuticals Inc. (Nasdaq: TCON) announced that the...

Company Drug

Hengrui Medicine’s Dalpiciclib Hits Superiority Criteria in Phase III Study

Fineline Cube Aug 30, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that its Phase III SHR6390-III-302 study...

Company

Ascentage Pharma’s H1 2022 Revenue Surges 636.9% on Olverembatinib Sales

Fineline Cube Aug 29, 2022

China-based Ascentage Pharma (HKG: 6855) reported a significant increase in revenue for the six months...

Company Policy / Regulatory

China-U.S. Listing Agreement Clears Path for Chinese Firms to Stay Listed in the U.S.

Fineline Cube Aug 29, 2022

China and the United States are nearing an agreement that would allow Chinese firms to...

Policy / Regulatory

Shandong Releases Off-Label Drug Use Consensus, Expanding Clinical Guidance

Fineline Cube Aug 29, 2022

The Shandong Pharmaceutical Association (SPA) has released the “Shandong Province Expert Consensus on Off-label Drug...

Company Drug

ImmuneOnco’s IMM40H Receives NMPA Clinical Trial Approval for CD70 Antibody

Fineline Cube Aug 29, 2022

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced that it has received clinical trial approval from the...

Company Deals

InnoCare Pharma Files for STAR Market IPO to Raise RMB 4B for Drug R&D

Fineline Cube Aug 29, 2022

China-based InnoCare Pharma (HKG: 9969) has filed for an initial public offering (IPO) on the...

Policy / Regulatory

NMPA Releases 57th Batch of Reference Drugs for Generic Consistency Evaluation

Fineline Cube Aug 29, 2022

The National Medical Products Administration (NMPA) has released the 57th batch of reference drugs for...

Company Deals Hospital

J&J MedTech Joins China’s Surgical Training Program to Skill Up Surgeons

Fineline Cube Aug 29, 2022

The National Institute of Hospital Administration (NIHA) and the National Health Commission (NHC) launched the...

Company Drug

Sirnaomics’ STP705 Achieves 100% Complete Remission in Basal Cell Carcinoma Study

Fineline Cube Aug 29, 2022

Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced positive results from a Phase II...

Policy / Regulatory

NMPA Reclassifies Omeprazole Tablets from Prescription to OTC Status

Fineline Cube Aug 29, 2022

The National Medical Products Administration (NMPA) announced that omeprazole enteric-coated tablets have been reclassified from...

Company Drug

Henlius Biotech’s PD-1 Inhibitor Serplulimab Secures NMPA Review for Esophageal Cancer

Fineline Cube Aug 29, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the National Medical Products Administration (NMPA) has...

Company Deals

Acchrom Tech Raises USD 14.45M in Angel Round Led by BioTrack Capital to Expand Chromatography Solutions

Fineline Cube Aug 29, 2022

Beijing-based chromatography specialist Acchrom Tech has raised RMB 100 million (USD 14.45 million) in an...

Company Legal / IP

JD Healthcare’s H1 2022 Financial Report Shows Strong Growth in Revenue and Profits

Fineline Cube Aug 26, 2022

JD Healthcare, a unit of China’s e-commerce giant JD.com (NASDAQ: JD), reported robust financial results...

Company

Everest Medicines CEO Resigns as Trodelvy Sale Completed

Fineline Cube Aug 26, 2022

China-based biotech Everest Medicines (HKG: 1952) announced the resignation of CEO Dr. Kerry Blanchard, effective...

Company Deals

Shanghai Bao Pharma Raises USD 100M in Series B to Advance Drug Delivery Tech

Fineline Cube Aug 26, 2022

Shanghai Bao Pharmaceuticals Co., Ltd has raised over USD 100 million in a Series B...

Company Deals

Lab Direct Raises USD 10M in Series A+ to Expand Digital Supply Chain Platform

Fineline Cube Aug 26, 2022

Shanghai-based life science digital supply chain platform Lab Direct has raised USD 10 million in...

Posts pagination

1 … 608 609 610 … 643

Recent updates

  • Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic
  • Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines
  • AstraZeneca’s Tezspire Gains Dual NMPA Approvals in China for Severe Asthma and Nasal Polyps Based on Pivotal Phase III Data
  • Medtronic’s Stealth AXiS Surgical System Gains FDA Approval for Cranial and ENT Procedures, Expanding Beyond Spine
  • Jenscare Completes First-in-Human Study of iJensRobo Robot-Assisted Tricuspid Valve Replacement System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Company Drug

Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines

Company Drug

AstraZeneca’s Tezspire Gains Dual NMPA Approvals in China for Severe Asthma and Nasal Polyps Based on Pivotal Phase III Data

Company Medical Device

Medtronic’s Stealth AXiS Surgical System Gains FDA Approval for Cranial and ENT Procedures, Expanding Beyond Spine

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.